Apart from complement deposition on the myelin sheath, increased serum and cerebrospinal fluid (CSF) levels of C5a and the soluble terminal complement complex C5b-9 have also been reported in newly diagnosed, treatment-naïve CIDP patients compared to controls [36]. The gene discussed is C5; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.